Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biol Chem. 2008 Jun;389(6):739-45. doi: 10.1515/BC.2008.085.

Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Author information

  • 1Program for Molecular Neuroscience, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. scarisbrick.isobel@mayo.edu

Abstract

Tissue kallikrein KLK1 and the kallikrein-related peptidases KLK2-15 are a subfamily of serine proteases that have defined or proposed roles in a range of central nervous system (CNS) and non-CNS pathologies. To further understand their potential activity in multiple sclerosis (MS), serum levels of KLK1, 6, 7, 8 and 10 were determined in 35 MS patients and 62 controls by quantitative fluorometric ELISA. Serum levels were then correlated with Expanded Disability Status Scale (EDSS) scores determined at the time of serological sampling or at last clinical follow-up. Serum levels of KLK1 and KLK6 were elevated in MS patients (p<or=0.027), with highest levels associated with secondary progressive disease. Elevated KLK1 correlated with higher EDSS scores at the time of serum draw and KLK6 with future EDSS worsening in relapsing remitting patients (p<or=0.007). Supporting the concept that KLK1 and KLK6 promote degenerative events associated with progressive MS, exposure of murine cortical neurons to either kallikrein promoted rapid neurite retraction and neuron loss. These novel findings suggest that KLK1 and KLK6 may serve as serological markers of progressive MS and contribute directly to the development of neurological disability by promoting axonal injury and neuron cell death.

PMID:
18627300
[PubMed - indexed for MEDLINE]
PMCID:
PMC2580060
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for iFactory Icon for PubMed Central
    Loading ...
    Write to the Help Desk